Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00064701 · ClinicalTrials.gov registry record · Phase 3
Comparative Study of Modified Release (MR) Tacrolimus/Mycophenolate Mofetil (MMF) in de Novo Kidney Transplant Recipients
A Phase 3 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 668
- Enrollment target
NCT00064701 is a Phase 3 study that has completed, run by Astellas Pharma. The registered enrollment target is 668 participants.
The verdict
NCT00064701, a Phase 3 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 668 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the safety and efficacy of tacrolimus/mycophenolate mofetil (MMF), cyclosporine/MMF and tacrolimus modified release/MMF in de novo kidney transplant recipients.
Interventions
- DRUG Tacrolimus
- DRUG mycophenolate mofetil
- DRUG Tacrolimus Modified Release (MR)
- DRUG cyclosporine microemulsion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 668 participants |
| Start Date | 2003-06 |
| Est. Completion | 2009-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00064701
The ClinicalTrials.gov registry entry for NCT00064701 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 668 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Tacrolimus is the first listed.
NCT00064701 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00064701 about?
NCT00064701 is a clinical study titled "Comparative Study of Modified Release (MR) Tacrolimus/Mycophenolate Mofetil (MMF) in de Novo Kidney Transplant Recipients". The purpose of this study is to compare the safety and efficacy of tacrolimus/mycophenolate mofetil (MMF), cyclosporine/MMF and tacrolimus modified release/MMF in de novo kidney transplant recipients.
What is the current status of trial NCT00064701?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 668 participants. The study started on 2003-06. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00064701?
The interventions under investigation include: Tacrolimus (DRUG), mycophenolate mofetil (DRUG), Tacrolimus Modified Release (MR) (DRUG), cyclosporine microemulsion (DRUG).
Who is sponsoring clinical trial NCT00064701?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.